HCW Biologics Inc Stock News

Watch the "What This Means" video here

Wugen closed a $115 million equity financing led by  Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he...

Lead product candidate will be advanced to late IND-enabling studies  to prepare for clinical trials for evaluation in the treatment of solid tumors

Company's pembrolizumab-based immune checkpoint inhibitor exhibited success  against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern University  on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or...

MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second qu...

Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated

MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC (“Nasd...

HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025